Passage Bio to Participate in Upcoming Investor Conferences
01 Agosto 2023 - 6:00AM
Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic
medicines company focused on developing transformative therapies
for central nervous system (CNS) disorders, today announced that
management will participate in the following upcoming investor
conferences:
Wedbush PacGrow Healthcare ConferenceFormat:
Management will participate in investor meetings Date: Tuesday,
August 8, 2023Location: New York, NY
Canaccord Genuity 43rd
Annual Growth ConferenceFormat: Presentation.Date:
Wednesday, August 9, 2023Time: 10:00 a.m. ETLocation: Boston,
MA
A live webcast of the presentation will be available on the
Investors & Media section of Passage Bio’s website at
investors.passagebio.com. A replay of the presentation will be
available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines
company on a mission to provide life-transforming therapies for
patients with CNS diseases with limited or no approved treatment
options. Our portfolio spans pediatric and adult CNS indications,
and we are currently advancing clinical programs in GM1
gangliosidosis and frontotemporal dementia and our preclinical
pipeline, including programs in amyotrophic lateral sclerosis and
Huntington’s disease. Based in Philadelphia, PA, our company has
established a strategic collaboration and licensing agreement with
the renowned University of Pennsylvania’s Gene Therapy Program to
conduct our discovery and IND-enabling preclinical work. Through
this collaboration, we have enhanced access to a broad portfolio of
gene therapy candidates and future gene therapy innovations that we
then pair with our deep clinical, regulatory, manufacturing and
commercial expertise to rapidly advance our robust pipeline of
optimized gene therapies. As we work with speed and tenacity, we
are always mindful of patients who may be able to benefit from our
therapies. More information is available
at www.passagebio.com.
For further information, please contact:
Investors:Stuart HendersonPassage
Bio267.866.0114shenderson@passagebio.com
Passage Bio Media:Mike BeyerSam Brown Inc. Healthcare
Communications312.961.2502mikebeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Passage Bio (NASDAQ:PASG)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024